

Product Name: BS-181 HCI Revision Date: 01/10/2020

Product Data Sheet

BS-181 HCI

Cat. No.: A5700

CAS No.: 1397219-81-6
Formula: C22H32N6·HCI


M.Wt: 416.99

Synonyms:

Target: Cell Cycle/Checkpoint

Pathway: Cyclin-Dependent Kinases

Storage: Store at -20°C



Solvent & Solubility

≥20.85mg/mL in DMSO, ≥6.49 mg/mL in EtOH with ultrasonic,insoluble in H2O

In Vitro

Preparing Stock Solutions	Mass			
	Solvent	1mg	5mg	10mg
	Concentration			
	1 mM	2.3981 mL	11.9907 mL	23.9814 mL
	5 mM	0.4796 mL	2.3981 mL	4.7963 mL
-10	10 mM	0.2398 mL	1.1991 mL	2.3981 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	CDK7 inhibitor,highly selective		
IC ₅₀ & Target	21 nM (CDK7)		
In Vitro	Cell Viability Assay		
	Cell Line:	MCF-7 cells	
	Preparation method:	The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.	
	Reacting conditions:	50 μM; 24 hrs	
	Applications:	In MCF-7 cells, BS-181 HCl inhibited the phosphorylation of CDK7 substrates,	

		and promoted cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines.				
	Animal experiment	Animal experiment				
In Vivo	Animal models:	Mice bearing MCF-7 xenografts				
	Dosage form:	10 or 20 mg/kg; i.p.; b.i.d., for 2 weeks				
	Applications:	In mice bearing MCF-7 xenografts, BS-181 HCl inhibited tumor growth in a dose-dependent manner, without apparent toxicity.				
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.				

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AG, Coombes RC. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009;69(15):6208-15.

APE BIC

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

APELLED ON THE OWN THE PARTY OF THE PARTY OF

APENTALISME TO SELECT TO THE PARTY OF THE PA

APETER BETTER

APENDER TO THE TOTAL STATE OF THE LIMITED TO

ARE Land to be for the form of the form of

APELLE TO THE PROPERTY OF THE

ARE HOLDEN

AP E Legate no Juntoni